Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates

Stock Track05-12

AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.

The company reported a net loss of $43.2 million for the quarter, which narrowed from a loss of $45.6 million a year earlier. While AbCellera beat analyst expectations for both earnings per share and revenue, posting a loss of $0.14 per share versus an estimated loss of $0.20 and revenue of $8.3 million versus an estimated $5.86 million, the market reaction was negative.

Investor concerns may stem from the company's continued substantial losses and increased research and development expenses, which climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter, though the company did announce positive interim Phase 1 clinical data for its ABCL635 candidate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141369593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141369593","market":"nz","top_or_hot":-1,"title":"Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates","media":"Stock Track","content":"<p>AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.</p><p>The company reported a net loss of $43.2 million for the quarter, which narrowed from a loss of $45.6 million a year earlier. While AbCellera beat analyst expectations for both earnings per share and revenue, posting a loss of $0.14 per share versus an estimated loss of $0.20 and revenue of $8.3 million versus an estimated $5.86 million, the market reaction was negative.</p><p>Investor concerns may stem from the company's continued substantial losses and increased research and development expenses, which climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter, though the company did announce positive interim Phase 1 clinical data for its ABCL635 candidate.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-12 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.</p><p>The company reported a net loss of $43.2 million for the quarter, which narrowed from a loss of $45.6 million a year earlier. While AbCellera beat analyst expectations for both earnings per share and revenue, posting a loss of $0.14 per share versus an estimated loss of $0.20 and revenue of $8.3 million versus an estimated $5.86 million, the market reaction was negative.</p><p>Investor concerns may stem from the company's continued substantial losses and increased research and development expenses, which climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter, though the company did announce positive interim Phase 1 clinical data for its ABCL635 candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1141369593","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141369593","pubTimestamp":1778535048,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.The company reported a net loss of $43.2 million for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"个股追踪|AbCellera Biologics盘后暴跌6.48%尽管超过Q1预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.The company reported a net loss of $43.2 million for the quarter, which narrowed from a loss of $45.6 million a year earlier. While AbCellera beat analyst expectations for both earnings per share and revenue, posting a loss of $0.14 per share versus an estimated loss of $0.20 and revenue of $8.3 million versus an estimated $5.86 million, the market reaction was negative.Investor concerns may stem from the company's continued substantial losses and increased research and development expenses, which climbed to $46.7 million from $42.5 million a year ago. Additionally, the number of downstream programs led by partners decreased to 40 from 44 at the end of the previous quarter, though the company did announce positive interim Phase 1 clinical data for its ABCL635 candidate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141369593","isCrawlerRequest":true}